阿替加奈盐酸

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 中文名称: 阿替加奈盐酸
• 英文名称: N-(1-naphthyl)-N'-(3-ethylphenyl)-N'-methylguanidine hydrochloride
• 英文别名: Aptiganel hydrochloride；N-(1-naphthyl)-N'-(3-ethylphenyl)-N'-methylguanidine；N-(1-naphthyl)-N'-(m-ethylphenyl)-N'-methylguanidine hydrochloride；N-(1-naphthyl)-N'-(3-ethylphenyl)-N'-methyl guanidine.HCl；aptiganel hydrochloride；1-(3-ethylphenyl)-1-methyl-2-naphthalen-1-ylguanidine;hydron;chloride
• 化学式: C₂₀H₂₁N₃*ClH
• 分子量: 339.868
• InChiKey: CKAKVKWRMCAYJD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.91
• 重原子数：
  24
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.15
• 拓扑面积：
  41.6
• 氢给体数：
  2
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  1-naphthylcyanamide 以 氯苯 为溶剂， 以3.1 g (8.1%, second crop)的产率得到阿替加奈盐酸
  参考文献：
  名称：

  Preparation of substituted guanidines

  摘要：

  通过在Lewis酸催化剂存在下，将取代氰胺基与氨或取代胺基反应，制备取代胍啉的方法。同时还披露了一种通过将单取代氰胺基与双取代胺基反应来制备三取代胍啉的方法。

  公开号：

  US05298657A1

文献信息

• Synthesis and structure-activity studies of N,N'-diarylguanidine derivatives. N-(1-naphthyl)-N'-(3-ethylphenyl)-N'-methylguanidine: a new, selective noncompetitive NMDA receptor antagonist
  作者：N. L. Reddy、Lain-Yen Hu、R. E. Cotter、J. B. Fischer、W. J. Wong、R. N. McBurney、E. Weber、D. L. Holmes、S. T. Wong

  DOI：10.1021/jm00028a009

  日期：1994.1

  hylguanidine (40) showed high affinity for the NMDA receptor ion channel site (IC50 = 36 nM vs [3H]-3) and low affinity for sigma receptors (IC50 = 2540 nM vs [3H]-5). Selectivity for the NMDA receptor ion channel sites over sigma receptors appears to be dependent upon the structure of the additional substituents on the guanidine nitrogen atoms bearing the aryl groups. Methyl and ethyl substituents

  作为NMDA受体离子通道位点配体的二芳基胍代表了一类潜在的神经保护药物。合成了与N，N'-二邻甲苯基胍（DTG）（一种已知的选择性sigma受体配体）结构相关的几种二芳基胍，并使用NMDA受体在大鼠或豚鼠脑膜匀浆中进行了体外放射性配体置换试验，并进行了评估。离子通道位点特异性放射性配体[3H]-（+）-5（S）-甲基-10（R），11-二氢-5H-二苯并[a，d]环庚烯-5，10-亚胺（MK-801，3 ），以及sigma受体特异性放射性配体[3H]-二邻甲苯基胍（DTG，5）。本文介绍了导致新的三和四取代的胍的结构-活性关系，其对NMDA受体离子通道位点具有高选择性，对sigma受体的亲和力弱或微不足道。对称取代的二苯基胍的体外结合结果表明，在苯环上具有邻或间取代基（相对于胍氮的位置）的化合物与对位取代的衍生物相比，对NMDA受体离子通道位点的亲和力更高。在针对对称二芳基胍研究的一组环取
• Therapeutic methods employing disulfide derivatives of dithiocarbamates and compositions useful therefor
  申请人：Medinox, Inc.

  公开号：US20030181495A1

  公开（公告）日：2003-09-25

  The present invention provides novel combinations of dithiocarbamate disulfide dimers with other active agents. In one method, the disulfide derivative of a dithiocarbamate is coadministered with a thiazolidinedione for the treatment of diabetes. In another embodiment, In another embodiment, invention combinations further comprise additional active agents such as, for example, metformin, insulin, sulfonylureas, and the like. In another embodiment, the present invention relates to compositions and formulations useful in such therapeutic methods.

  本发明提供了二硫代氨基甲酸盐二硫化二聚体与其他活性药剂的新组合。在一种方法中，二硫代氨基甲酸盐的二硫化衍生物与噻唑烷二酮联合用于治疗糖尿病。在另一实施例中，该发明的组合进一步包括额外的活性药剂，例如二甲双胍、胰岛素、磺酰脲类药物等。在另一实施例中，本发明涉及用于这种治疗方法的组合物和配方。
• Tri- and tetra-substituted guanidines and their use as excitatory amino
  申请人：State of Oregon

  公开号：US05262568A1

  公开（公告）日：1993-11-16

  Tri- and tetra-substituted guanidines which exhibit a high binding affinity to phencyclidine (PCP) receptors and, more preferably, low affinity to the brain sigma receptors. These guanidine derivatives act as non-competitive inhibitors of glutamate induced responses of the NMDA receptor by acting as blockers for the ion channel of the NMDA receptor-ion channel complex. These compounds thus exert neuroprotective activity and are useful in the therapeutic treatment of neuronal loss in hypoxia, hypoglycemia, brain or spinal cord ischemia, and brain or spinal chord trauma as well as being useful for the treatment of epilepsy, Alzheimer's disease, Amyotrophic Lateral Sclerosis, Parkinson's disease, Huntington's disease, Down's Syndrome, Korsakoff's disease and other neurodegenerative disorders.

  三取代和四取代的胍基化合物对苯环利定（PCP）受体具有高结合亲和力，更好的是，对大脑西格玛受体具有低亲和力。这些胍基衍生物作为非竞争性抑制剂，通过作为NMDA受体离子通道复合物的通道阻滞剂，阻止谷氨酸诱导的NMDA受体响应。这些化合物因此具有神经保护作用，可用于治疗缺氧、低血糖、脑或脊髓缺血、脑或脊髓创伤引起的神经元丧失，以及用于治疗癫痫、阿尔茨海默病、肌萎缩性侧索硬化、帕金森病、亨廷顿病、唐氏综合征、科萨科夫病和其他神经退行性疾病。
• Tri-and tetra-substituted guanidines and their use as excitatory amino
  申请人：State of Oregon, acting by and through the Oregon State Board of Higher

  公开号：US05767162A1

  公开（公告）日：1998-06-16

  Tri- and tetra-substituted guanidines which exhibit a high binding affinity to phencyclidine (PCP) receptors and, more preferably, low affinity to the brain sigma receptors. These guanidine derivatives act as non-competitive inhibitors of glutamate induced responses of the NMDA receptor by acting as blockers for the ion channel of the NMDA receptor-ion channel complex. These compounds thus exert neuroprotective activity and are useful in the therapeutic treatment of neuronal loss in hypoxia, hypoglycemia, brain or spinal cord ischemia, and brain or spinal chord trauma as well as being useful for the treatment of epilepsy, Alzheimer's disease, Amyotrophic Lateral Sclerosis, Parkinson's disease, Huntington's disease, Down's Syndrome, Korsakoff's disease and other neurodegenerative disorders.

  三取代和四取代的胍基化合物具有高结合亲和力，可与苯环哌啶（PCP）受体结合，并更倾向于低亲和力与大脑西格玛受体结合。这些胍基衍生物作为非竞争性抑制剂，通过阻断NMDA受体离子通道复合物的离子通道作用，从而抑制谷氨酸诱导的NMDA受体反应。这些化合物因此具有神经保护作用，并可用于治疗缺氧、低血糖、脑或脊髓缺血、脑或脊髓创伤以及癫痫、阿尔茨海默病、肌萎缩性侧索硬化、帕金森病、亨廷顿病、唐氏综合症、科萨科夫病和其他神经退行性疾病的治疗。
• Tri-and tetra-substituted guanidines and their use as excitatory amino acid antagonists
  申请人：State of Oregon, acting by and through the Oregon State Board of Higher Education, acting for and on behalf of the Oregon Health Sciences University and the University of Oregon

  公开号：US06251948B1

  公开（公告）日：2001-06-26

  Tri- and tetra-substituted guanidines which exhibit a high binding affinity to phencyclidine (PCP) receptors and, more preferably, low affinity to the brain sigma receptors. These guanidine derivatives act as non-competitive inhibitors of glutamate induced responses of the NMDA receptor by acting as blockers for the ion channel of the NMDA receptor-ion channel complex. These compounds thus exert neuroprotective activity and are useful in the therapeutic treatment of neuronal loss in hypoxia, hypoglycemia, brain or spinal cord ischemia, and brain or spinal chord trauma as well as being useful for the treatment of epilepsy, Alzheimer's disease, Amyotrophic Lateral Sclerosis, Parkinson's disease, Huntington's disease, Down's Syndrome, Korsakoff's disease and other neurodegenerative disorders.

  三取代和四取代的胍基化合物具有高结合亲和力，可以结合到苯环环庚啡（PCP）受体，更好的是，这些化合物对大脑σ受体的亲和力较低。这些胍基衍生物作为非竞争性抑制剂，通过作为NMDA受体离子通道复合物的通道阻滞剂，来抑制谷氨酸诱导的NMDA受体响应。因此，这些化合物具有神经保护作用，并可用于治疗缺氧、低血糖、脑或脊髓缺血、脑或脊髓创伤以及癫痫、阿尔茨海默病、肌萎缩性侧索硬化症、帕金森病、亨廷顿病、唐氏综合症、科萨科夫氏综合症和其他神经退行性疾病的治疗。